Drug profile · INN
retapamulin
ALTARGO
retapamulin (ALTARGO) is a 70s ribosome inhibitor. Associated with Almirall, S.A.. Route of administration: topical. Current US regulatory status: approved.
Drug details — retapamulin
- US status
- approved
- Class
- Dermatologicals (D06)
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
retapamulin (ALTARGO) is a 70s ribosome inhibitor. Associated with Almirall, S.A.. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
70S ribosome inhibitor
Primary target: 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is retapamulin?
retapamulin (ALTARGO) is a 70s ribosome inhibitor. Associated with Almirall, S.A.. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for retapamulin?
ALTARGO is a marketed brand name for retapamulin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of retapamulin?
retapamulin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.